US20160237030A1 - Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof - Google Patents

Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof Download PDF

Info

Publication number
US20160237030A1
US20160237030A1 US15/028,773 US201415028773A US2016237030A1 US 20160237030 A1 US20160237030 A1 US 20160237030A1 US 201415028773 A US201415028773 A US 201415028773A US 2016237030 A1 US2016237030 A1 US 2016237030A1
Authority
US
United States
Prior art keywords
compound
preparation
borane
give
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/028,773
Other languages
English (en)
Inventor
Guojun Zheng
Yaping Wang
Shi Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Assigned to ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. reassignment ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FENG, SHI, WANG, YAPING, ZHENG, GUOJUN
Publication of US20160237030A1 publication Critical patent/US20160237030A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1856—
    • C07C2101/14—
    • C07C2102/24—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a preparation method of a drug, specifically, the present invention relates to a preparation method of Maxacalcitol, a novel synthetic intermediate thereof, a preparation method and a use therefor.
  • Maxacalcitol (Maxacalcitol, CAS NO.: 103909-75-7), whose English chemical formula is: 22-Oxacalcitriol; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1S,3aS,7aS)-octahydro-1-[(1S)-1-(3-hydroxy-3-Methylbutoxy)ethyl]-7a-Methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol, is the third generation of active vitamin D3 drug developed by Chugai Pharmaceutical Co., Ltd., and first faced to the market in Japan in 2000, its injection (Trade name: Oxarol) is used for treating the secondary hyperparathyroidism of the renal dialysis patients (SHPT); its ointment (Trade name: Oxarol) is used for treating the dry tinea skin diseases such as psoriasis.
  • U.S. Pat. No. 5,436,401A discloses a preparation method of Maxacalcitol, in which la-hydroxyl dehydroepiandrosterone is used as a starting material, and Maxacalcitol is given through modification on side chain and ring A, opening ring B by photochemical reaction and rearrangement under heating condition.
  • 1 ⁇ -hydroxyl dehydroepiandrosterone is prepared by microbial fermentation, which greatly restricts the source of the starting material, and the preparation method involves multiple reaction steps, some of which have relative low yields, which is not suitable for industrial production.
  • WO2012/122451 improves the preparation method of Maxacalcitol greatly and reduces the reaction steps by introducing a product as the starting material which is obtained by proper modifying an analog compound of vitamin D2.
  • the improved method employs NaBH 4 when reducing the ketone at C-20 position, the main product of which is with opposite configuration, this greatly restricts the application of the process.
  • CN102796134 aims mainly at the shortage of the process in WO2012/122451, focuses on improving the reduction of the ketone at C-20 position disclosed in WO2012/122451, and obtains the product with single configuration through asymmetric reduction.
  • JP20111573261 takes vitamin D2 as the starting material, and obtains compound X according to the method in U.S. Pat. No. 4,866,048, the compound X is converted into compound V′(S configuration) and V′′(R configuration) with a ratio of 35:65 under the action of lithium aluminium hydride, the compound V′(S configuration) is the target configuration (with a yield of 24% only), the synthesis efficiency is too low.
  • One of the aims of the present invention is to provide a novel key intermediate (compound III, IV, VI) and preparation method thereof.
  • Another aim of the present invention is to provide a novel preparation method of Maxacalcitol by using the key intermediate.
  • One aspect of the present invention is to provide a novel intermediate represented by Formula III used for the synthesis of Maxacalcitol:
  • R is H or a hydroxyl protection group, wherein the hydroxyl protection group includes a silicon ether protection group, preferably is a t-butyldimethylsilyl, a trimethylsilyl, a triethylsilyl, a t-butyldiphenylsilyl or a triisoprolylsilyl.
  • Another aspect of the present invention is to provide a preparation method of compound III, comprising in the presence of a catalyst, oxidating compound II with an oxidizing agent to afford compound III, where R is defined as above:
  • the oxidizing agent of the oxidation reaction is preferably oxygen;
  • the catalyst is preferably a copper catalyst, more preferably 2,2-bipyridine copper complex.
  • Another aspect of the present invention is to provide a novel intermediate represented by Formula IV used for the synthesis of Maxacalcitol:
  • R is H or a hydroxyl protection group, wherein the hydroxyl protection group comprises a silicon ether protection group, preferably is a t-butyldimethylsilyl, a trimethylsilyl, a triethylsilyl, a t-butyldiphenylsilyl or a triisoprolylsilyl.
  • Another aspect of the present invention is to provide a preparation method of compound IV, comprising:
  • the chiral auxiliary reagent used in the reaction is preferably selected from (R)-2-methyl-CBS-oxazaborolidine, (R)-2-ethyl-CBS-oxazaborolidine or (R)-2-isopropyl-CBS-oxazaborolidine;
  • the borane used in the reaction is preferably selected from BH 3 , borane-tetrahydrofuran complex, borane-triethylamine complex, borane-ethyl ether complex, borane-methyl sulfide complex or borane-N,N-diethylaniline complex.
  • a mole ratio of the compound III, the chiral auxiliary reagent and the borane is preferably 1:(0.1-1):(1-2), more preferably 1:0.6:1.
  • the reaction temperature is preferably ⁇ 60° C. to 0° C., more preferably ⁇ 20° C.
  • Another aspect of the present invention is to provide a novel intermediate represented by Formula VI for the synthesis of Maxacalcitol:
  • R is H or a hydroxyl protection group, wherein the hydroxyl protection group includes a silicon ether protection group, preferably is a t-butyldimethylsilyl, a trimethylsilyl, a triethylsilyl, a t-butyldiphenylsilyl or a triisoprolylsilyl.
  • Another aspect of the present invention is to provide a preparation method of compound VI, comprising:
  • Step 1 converting compound IV into compound V under alkaline condition:
  • R is a hydroxyl protection group
  • Step 2 reacting compound V with 3-bromomethyl-2,2-dimethyloxirane to give compound VI:
  • R is a hydroxyl protection group
  • the preparation method of compound VI can further comprises: de-protecting the hydroxyl protection group R of compound VI which is obtained in the step 2 to give compound VI:
  • the alkali in the step 1 includes sodium bicarbonate or sodium acetate.
  • Another aspect of the present invention is to provide a preparation method of Maxacalcitol represented by formula I:
  • the preparation method comprises:
  • Step 1 converting compound IV into compound V under alkaline condition:
  • R is a hydroxyl protection group
  • Step 2 reacting compound V with 3-bromomethyl-2,2-dimethyloxirane to give compound VI:
  • R is a hydroxyl protection group
  • Step 3 converting compound VI into compound VII in the presence of lithium triisobutylhydroborate:
  • R is a hydroxyl protection group
  • Step 4 reacting compound VII under the action of both N-methylmorpholine N-oxide and selenium dioxide to give compound VIII:
  • R is a hydroxyl protection group
  • Step 5 de-protecting the hydroxyl protection group of compound VIII to give compound IX:
  • R is a hydroxyl protection group
  • Step 6 conducting a photochemical reaction on compound IX to give Maxacalcitol represented by formula I:
  • the alkali in the step 1 includes sodium bicarbonate or sodium acetate.
  • a preparation method of Maxacalcitol which comprises:
  • the mass ratio of compound IX to 9-acetylanthracene is preferably 1:(0.05-1), more preferably 1:0.1.
  • the duration of the reaction can be 0.5 to 5 h, preferably 2 h.
  • the reaction temperature is preferably 0° C. to 10° C.
  • the reaction can be conducted in a proper organic solvent
  • the organic solvent can be any proper one, including but not limited to, methanol, ethanol, acetone, dioxane, acetonitrile, THF.
  • compound IX can be prepared according to a preparation method as below:
  • a molar ratio of compound VIII-1 to tetrabutylammonium fluoride is preferably 1:1-3, more preferably 1:1.5.
  • the duration of the reaction can be 5 h to 40 h, preferably 10 h.
  • the reaction temperature is preferably 65° C.
  • the reaction can be conducted in a proper organic solvent
  • the organic solvent can be any proper one, including but not limited to, methanol, ethanol, acetone, dioxane, acetonitrile, THF, preferably THF.
  • compound VIII-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound VII-1, N-methylmorpholine N-oxide and selenium dioxide is preferably 1:(1-3):(0.2-1), more preferably 1:2:0.4.
  • the duration of the reaction can be 2 h to 24 h, preferably 8 h.
  • the reaction temperature is preferably 35° C.
  • compound VII-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound VI-1 to lithium triisobutylhydroborate is preferably 1:(1-3), more preferably 1:1.5.
  • the duration of the reaction can be 1 h to 10 h, preferably 3 h.
  • the reaction temperature is preferably 25° C.
  • the solvent is preferably THF.
  • compound VI-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound V-1, sodium hydride and 3-bromomethyl-2,2-dimethyloxirane is preferably 1:(1-3):(1-3), more preferably 1:1.2:2.
  • the duration of the reaction can be 1 h to 10 h, preferably is 5 h.
  • the reaction temperature is preferably 50° C.
  • the reaction can be conducted in a proper organic solvent
  • the organic solvent can be any proper one, including but not limited to, dioxane, acetonitrile, THF, DMF, DMSO, N,N-dimethylacetamide or N-methylpyrrolidone, etc.
  • compound V-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound IV-1 to sodium bicarbonate is preferably 1:(1-10), more preferably 1:6.
  • the duration of the reaction can be 1 h to 24 h, preferably 7 h.
  • the reaction temperature is preferably 80° C.
  • the reaction can be conducted in a proper organic solvent
  • the organic solvent can be any proper one, including but not limited to, 95% (v/v) ethanol, acetonitrile, ethyl acetate or anhydrous ethanol, preferably 95% (v/v) ethanol.
  • compound IV-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound III-1, (R)-2-methyl-CBS-oxazaborolidine and borane is preferably 1:(0.1-1):(1-2), more preferably 1:0.6:1.
  • the reaction temperature can be ⁇ 60° C. to 0° C., preferably ⁇ 20° C.
  • the duration of the reaction is preferably 3 h.
  • compound III-1 can be prepared according to a preparation method as below:
  • a molar ratio of compound II-1, triethylenediamine, 2,2-bipyridine and copper acetate is preferably 1:(1-2):(0.1-1):(0.1-1), more preferably 1:1:0.2:0.2.
  • the duration of the reaction can be 1 h to 20 h, preferably 5 h.
  • the reaction temperature is preferably 45° C.
  • compound II-1 is prepared according to patent U.S. Pat. No. 4,866,048.
  • the present invention has the following advantages:
  • the synthetic process provided by the present invention is crafty-designed, in which vitamin D2 is used as a starting material, compound II is prepared according to the method in U.S. Pat. No. 4,866,048 and then oxidized by oxygen under copper catalysis to deliver compound III.
  • compound II is prepared according to the method in U.S. Pat. No. 4,866,048 and then oxidized by oxygen under copper catalysis to deliver compound III.
  • the oxidation process due to the protection of sulfur dioxide for the double bond, other side reactions are reduced, which make the yield of oxidation product reach about 80%.
  • the yield is relative low due to the unstability of the conjugated triple bond, for example, the yield of oxidation reaction mentioned in JP20111573261 is 67% and in reference T.L. 1994, 2295-2298 is 60%-65%.
  • compound III is reduced stereoselectively to give compound IV with single S configuration by employing a borane, and with a high yield of nearly 100%.
  • sulfur dioxide protects the terminal double bond
  • side reaction which is the reaction between the borane and the terminal double bond can be efficiently avoided in the reduction reaction, which improves the yield.
  • WO2012/122451 and JP20111573261 conduct the reduction reaction by employing sodium borohydride/lithium aluminum hydride, in which the majority of the product is with R configuration, the yield of product with S configuration is extremely low, furthermore, the products with two configurations have close Rf values, which leads to difficult purification.
  • the present invention protects the double bond with sulfur dioxide, which plays an important role in the oxidation and asymmetric reduction steps, efficiently avoids other side reactions, and improves the reaction yield dramatically. Meanwhile, the following purification becomes much easier since the product with single S configuration is given. The synthesis efficiency is greatly improved, and the process cost is greatly reduced.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
US15/028,773 2013-10-12 2014-10-11 Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof Abandoned US20160237030A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310475989.7A CN103508999B (zh) 2013-10-12 2013-10-12 马沙骨化醇的合成中间体及其制备方法和用途
CN201310475989.7 2013-10-12
PCT/CN2014/088336 WO2015051762A1 (zh) 2013-10-12 2014-10-11 马沙骨化醇的合成中间体及其制备方法和用途

Publications (1)

Publication Number Publication Date
US20160237030A1 true US20160237030A1 (en) 2016-08-18

Family

ID=49892479

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/028,773 Abandoned US20160237030A1 (en) 2013-10-12 2014-10-11 Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof

Country Status (8)

Country Link
US (1) US20160237030A1 (ja)
EP (1) EP3056491B1 (ja)
JP (1) JP2016534151A (ja)
CN (1) CN103508999B (ja)
CA (1) CA2926961C (ja)
IL (1) IL245018A (ja)
RU (1) RU2650192C2 (ja)
WO (1) WO2015051762A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103508999B (zh) * 2013-10-12 2015-05-13 浙江海正药业股份有限公司 马沙骨化醇的合成中间体及其制备方法和用途
CN107176918A (zh) * 2016-03-09 2017-09-19 湖南华腾制药有限公司 一种马沙骨化醇的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772433A (en) * 1981-11-02 1988-09-20 Research Institute For Medicine And Chemistry Inc. Vitamin D analogues
US4866048A (en) * 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US20110157326A1 (en) * 2009-12-31 2011-06-30 Broadcom Corporation Multi-path and multi-source 3d content storage, retrieval, and delivery
JP2011157326A (ja) * 2010-02-03 2011-08-18 Formosa Lab Inc マキサカルシトール中間体およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024108A (ja) 1983-07-18 1985-02-06 株式会社クボタ 自動走行作業車
JP3493037B2 (ja) 1991-12-18 2004-02-03 中外製薬株式会社 ２２−オキサコレカルシフェロール誘導体とその製造方法
GB9314400D0 (en) * 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
EP1426352A2 (en) * 1996-09-03 2004-06-09 The Trustees of Columbia University in the City of New York Intermediates for the sythesis of vitamin D and steroid derivatives
IT1311923B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
EP1275643A4 (en) 2000-04-19 2009-06-03 Chugai Pharmaceutical Co Ltd DERIVATIVES OF VITAMIN D
EP1556345B1 (en) * 2002-10-23 2010-12-15 Leo Pharma A/S Vitamin d analogues, compositions comprising said analogues and their use
JP2014514274A (ja) * 2011-03-09 2014-06-19 テバ ファーマシューティカル インダストリーズ リミティド マキサカルシトールの多形およびマキサカルシトールの調製方法
CN102796134B (zh) * 2012-08-31 2015-07-01 甘肃皓天化学科技有限公司 一种马沙骨化醇中间体的制备方法
CN103508999B (zh) * 2013-10-12 2015-05-13 浙江海正药业股份有限公司 马沙骨化醇的合成中间体及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772433A (en) * 1981-11-02 1988-09-20 Research Institute For Medicine And Chemistry Inc. Vitamin D analogues
US4866048A (en) * 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US20110157326A1 (en) * 2009-12-31 2011-06-30 Broadcom Corporation Multi-path and multi-source 3d content storage, retrieval, and delivery
JP2011157326A (ja) * 2010-02-03 2011-08-18 Formosa Lab Inc マキサカルシトール中間体およびその製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anderson "Development of an Improved Process for Doxercalciferol via a Continuous Photochemical Reaction" Org. Process Res. Dev. 2012, 16, 967−975. *
Andrews "Synthesis of 25-Hydroxy- and la,25-Dihydroxyvitamin D3 from Vitamin D2" J. Org. Chem. 1986, 51, 4819-4828. *
Corey "Reduction of Carbonyl Compounds with Chiral Oxazaborolidine Catalysts: A New Paradigm for Enantioselective Catalysis and a Powerful New Synthetic Method" Angew. Chem. Int. Ed. 1998, 37, 1986-2012. *
Moriarty "Synthesis of 1R-Hydroxyvitamin D5 Using a Modified Two Wavelength Photolysis for Vitamin D Formation" J. Org. Chem. 2005, 70, 7624-7628. *

Also Published As

Publication number Publication date
IL245018A0 (en) 2016-05-31
CA2926961C (en) 2018-12-18
RU2016115929A3 (ja) 2018-03-22
CA2926961A1 (en) 2015-04-16
IL245018A (en) 2017-10-31
WO2015051762A1 (zh) 2015-04-16
EP3056491B1 (en) 2018-08-08
EP3056491A4 (en) 2017-04-26
CN103508999A (zh) 2014-01-15
EP3056491A1 (en) 2016-08-17
RU2650192C2 (ru) 2018-04-11
RU2016115929A (ru) 2017-11-17
CN103508999B (zh) 2015-05-13
JP2016534151A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
Sharpless et al. Mild procedure for the conversion of epoxides to allylic alcohols. First organoselenium reagent
Brown et al. Hydroboration. 61. Diisopinocampheylborane of high optical purity. Improved preparation and asymmetric hydroboration of representative cis-disubstituted alkenes
US20210070771A1 (en) Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
JP5490155B2 (ja) プロスタグランジン誘導体の製造方法
US9828323B2 (en) Process for preparation of MK-7 type of vitamin K2
D'Aniello et al. 1, 3-diastereocontrol with bromoallenes. Synthesis of enantiomerically pure β-branched α-amino acids
EP3056491B1 (en) Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof
Concellón et al. An improved preparation of epoxides from carbonyl compounds by using diiodomethane/methyllithium: synthetic applications
JP5563324B2 (ja) マキサカルシトール中間体およびその製造方法
WO2021071372A1 (en) Process of vitamin k2 derivatives preparation
US20240174627A1 (en) Catalytic cannabinol synthesis and precursors
US20180009745A1 (en) Process for the preparation of a polyunsaturated ketone compound
US4292249A (en) 25-Hydroxy-24-oxocholestane derivatives and preparation thereof
EP1506958B1 (en) Process for producing shogaol and intermediates for the synthesis thereof
US11174275B2 (en) Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use
Richter et al. Synthesis of muscalure and homologous hydrocarbons
Obijalska et al. A new approach to α-(trifluoromethyl) benzyl substituted oxaziridines
CN115947678B (zh) 稳定同位素2h（d）标记25-羟基维生素d2的合成方法
CN110627718B (zh) 一种(E)-β-单氟烷基-β,γ-不饱和酰胺的合成方法
CN110642689B (zh) 一种3,6-二溴-2-甲基苯甲醛及其化学合成方法
JP2501604B2 (ja) コレスタ―１，４，６−トリエン−３−オン類の製造法
CN107721918B (zh) 一种2,6-二烷基-3,5-二酯基对称吡啶的制备方法
JPS61145139A (ja) コレカルシフエロール誘導体
KR101019787B1 (ko) 칸타잔틴의 제조방법
US20240116843A1 (en) Process for the preparation of vitamin k2 and novel intermediates

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHENG, GUOJUN;FENG, SHI;WANG, YAPING;REEL/FRAME:038414/0213

Effective date: 20160401

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION